pharmaphorum

NOVEMBER 17, 2022

Leela Barham argues that more transparency at a minimum is required next time around, should a VPAS style of agreement be agreed upon for 2024 onwards, and perhaps even a more radical re-think about how a deal is struck in the future. About the author. But could it be better than what has been done since 1957?

Government 96

Government Sales Medicine Consulting 96

pharmaphorum

AUGUST 17, 2022

The indicators did not bring universal good news , but Leela Barham argues we need to consider whether the indicators are measuring what matters most if we are to understand more about the health of the UK life sciences industry and, most importantly, what it means for patients. About the author.

Competition 58

Competition Medicine Patients Government 58

pharmaphorum

OCTOBER 24, 2022

With the IMF not yet used, but based on the Cancer Drugs Fund (CDF), Leela Barham used a freedom of information request to find out how the CDF spend is treated, and speculates as to what that might mean for the IMF. About the author. 2019 VPAS shapes commercial realities for companies.

Medicine 72

Medicine Sales Specialization Marketing 72

pharmaphorum

DECEMBER 8, 2022

Leela Barham calls for more transparency on the LSC when it’s needed most. About the author. Leela Barham is a researcher and writer who has worked with all stakeholders across the health care system, both in the UK and internationally, on the economics of the pharmaceutical industry. Life Sciences Council.

Government 91

Government Medicine Pharmaceutical Patients 91

pharmaphorum

JANUARY 20, 2023

Leela Barham argues that the latest operational guidance for the NHS in England continues to illustrate a disconnect between the messages in big-ticket policy documents from the central government and the messages from the NHS in England on medicines. On the money side, all stakeholders need to get their thinking caps on!

Medicine 93

Medicine Government Patients Management 93